57 completed. 57 Phase 2, 11 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 57 | Completed 57 |
| Phase 1 | 11 | Completed 11 |
| Phase 3 | 1 | Completed 1 |
Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 47 | 2020-11-09 | 2026-03-02 |
| Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Palbociclib, Temozolomide, Irinotecan - Ewing Sarcoma, Solid Tumors | Phase 2 | Completed | Pfizer | 128 | 2019-05-24 | 2026-10-07 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids - Neuroendocrine Tumors, Meningioma | Phase 2 | Completed | University of Iowa | 39 | 2017-09-29 | 2023-02-09 |
| A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Pomalidomide - Central Nervous System Neoplasms, Medulloblastoma | Phase 2 | Completed | Celgene | 53 | 2017-09-18 | 2024-04-16 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors 68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Completed | Sue O'Dorisio | 122 | 2015-09-01 | 2020-12-21 |
| Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma radiation therapy, temozolomide, plerixafor - Adult Ependymoblastoma, Adult Giant Cell Glioblastoma | Phase 1 / Phase 2 | Completed | Lawrence Recht | 30 | 2014-11-01 | 2018-10-23 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
| Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Carboplatin, Cognitive Assessment, Cyclophosphamide - Desmoplastic/Nodular Medulloblastoma, Medulloblastoma | Phase 2 | Completed | Children's Oncology Group | 26 | 2013-12-24 | 2023-01-09 |
| A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) LDE225, TMZ - Medulloblastoma | Phase 2 | Completed | Novartis Pharmaceuticals | 22 | 2013-05-06 | 2017-08-11 |
| Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide - Adult Medulloblastoma, Childhood Medulloblastoma | Phase 2 | Completed | Sue O'Dorisio | 68 | 2013-04-01 | 2021-09-22 |
| Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors 68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors | Phase 1 / Phase 2 | Completed | Sue O'Dorisio | 223 | 2012-02-21 | 2021-07-27 |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB LDE225 - Medulloblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2011-02-01 | 2017-03-20 |
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2010-11-22 | 2021-07-23 |
| Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib - Recurrent Childhood Medulloblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2010-11-01 | 2016-01-14 |
Showing 20 of 57. Sign in to see all of them.
Central Nervous System Neoplasms (31) · Neuroblastoma (23) · Astrocytoma (22) · Glioma (20) · Ependymoma (19) · Brain Neoplasms (17) · Familial ependymoma (17) · Oligodendroglioma (16) · Glioblastoma (14) · Osteosarcoma (12) · Sarcoma (12) · Neuroectodermal Tumors, Primitive (11) · Rhabdomyosarcoma (11) · Gliosarcoma (10)
Neoplasms by Histologic Type (57) · Neoplasms, Glandular and Epithelial (57) · Neoplasms, Nerve Tissue (57) · Neoplasms, Neuroepithelial (56) · Neoplasms (55) · Neoplasms, Germ Cell and Embryonal (55) · Neuroectodermal Tumors (55) · Neuroectodermal Tumors, Primitive (46) · Neoplasms by Site (43) · Nervous System Diseases (41) · Nervous System Neoplasms (40) · Glioma (37) · Central Nervous System Diseases (26) · Brain Diseases (25) · Neoplasms, Connective and Soft Tissue (18)
Cyclophosphamide (10) · Filgrastim (8) · Irinotecan (7) · Radiotherapy (7) · Temozolomide (7) · Cisplatin (6) · Peripheral Blood Stem Cell Transplantation (6) · Carboplatin (5) · Etoposide (5) · Vincristine (5) · Thiotepa (4) · Chemotherapy, Adjuvant (3) · Magnetic Resonance Spectroscopy (3) · Topotecan (3) · sargramostim (3)
National Cancer Institute (NCI) (15) · Duke University (4) · Children's Oncology Group (3) · Sue O'Dorisio (3) · Eli Lilly and Company (2) · Herbert Irving Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Barbara Ann Karmanos Cancer Institute (1) · Celgene (1) · Children's Cancer and Leukaemia Group (1) · Children's Hospital Los Angeles (1) · Dr Andrea Rossetti (1)
United States (50) · Canada (13) · Australia (10) · Puerto Rico (10) · France (6) · United Kingdom (6) · Germany (5) · Italy (5) · Spain (5) · Switzerland (5) · Netherlands (4) · New Zealand (3) · Belgium (2) · Brazil (2) · Poland (2)
Darell D. Bigner, MD, PhD (3) · Amar Gajjar (2) · Charles S. Hesdorffer, MD (2) · Maryam Fouladi (2) · Adam S Levy (1) · Andrea O. Rossetti, MD (1) · Anne-Marie Langevin, MD (1) · Barry Pizer, MD (1) · Birgit Geoerger, MD (1) · Brian H. Kushner, MD (1)
PMID 31401903, PMID 26169613, PMID 11835236, PMID 16408203, PMID 16532433, PMID 16549835, PMID 17019740, PMID 17610262, PMID 18623206, PMID 18989154, PMID 20943374, PMID 28153957, PMID 29181270, PMID 33025730, PMID 34168987, PMID 38815151, PMID 39298716, PMID 40721826, PMID 42788739
U10CA180886 (6), U10CA098543 (5), U01CA081457 (4), R01CA167632 (2), 2016 (1), 2019 (1), 2023 (1), P30CA008748 (1), P30CA022453 (1), P30CA086862 (1), P30CA124435 (1), U10CA081851 (1), U10CA081920 (1), UM1CA097452 (1)